ANIP Stock Overview
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
ANI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.30 |
| 52 Week High | US$70.81 |
| 52 Week Low | US$48.20 |
| Beta | 0.71 |
| 11 Month Change | -7.83% |
| 3 Month Change | -8.45% |
| 1 Year Change | -1.00% |
| 33 Year Change | 77.64% |
| 5 Year Change | -20.27% |
| Change since IPO | 825.40% |
Recent News & Updates
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Recent updates
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16ANI Pharmaceuticals Q2 2022 Earnings Preview
Aug 05Shareholder Returns
| ANIP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.4% | -1.4% | 0.6% |
| 1Y | -1.0% | 22.2% | 32.1% |
Return vs Industry: ANIP underperformed the US Pharmaceuticals industry which returned 22.3% over the past year.
Return vs Market: ANIP underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| ANIP volatility | |
|---|---|
| ANIP Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ANIP has not had significant price volatility in the past 3 months.
Volatility Over Time: ANIP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 642 | Nikhil Lalwani | www.anipharmaceuticals.com |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals.
ANI Pharmaceuticals, Inc. Fundamentals Summary
| ANIP fundamental statistics | |
|---|---|
| Market cap | US$1.12b |
| Earnings (TTM) | US$22.93m |
| Revenue (TTM) | US$538.95m |
49.6x
P/E Ratio2.1x
P/S RatioIs ANIP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANIP income statement (TTM) | |
|---|---|
| Revenue | US$538.95m |
| Cost of Revenue | US$208.38m |
| Gross Profit | US$330.58m |
| Other Expenses | US$307.65m |
| Earnings | US$22.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.17 |
| Gross Margin | 61.34% |
| Net Profit Margin | 4.25% |
| Debt/Equity Ratio | 59.4% |
How did ANIP perform over the long term?
See historical performance and comparison